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Original Article
Utility of the Neuropsychiatric  
Inventory Questionnaire (NPI-Q) in the 
assessment of a sample of patients with 
Alzheimer’s disease in Chile
Gada Musa1,2,5,8, Fernando Henríquez1,4, Carlos Muñoz-Neira1,8,  
Carolina Delgado3, Patricia Lillo6,9, Andrea Slachevsky1,4,5,6,7
ABSTRACT. The Neuropsychiatric Inventory Questionnaire (NPI-Q) is an informant-based instrument that measures the 
presence and severity of 12 Neuropsychiatric Symptoms (NPS) in patients with dementia, as well as informant distress. 
Objective: To measure the psychometric properties of the NPI-Q and the prevalence of NPS in patients with Alzheimer’s 
disease (AD) in Chile. Methods: 53 patients with AD were assessed. Subjects were divided into two different groups: mild 
AD (n=26) and moderate AD (n=27). Convergent validity was estimated by correlating the outcomes of the NPI-Q with 
Neuropsychiatric Inventory (NPI) scores and with a global cognitive efficiency test (Addenbrooke’s Cognitive Examination 
– Revised – ACE-R). Reliability of the NPI-Q was analysed by calculating its internal consistency. Prevalence of NPS was 
estimated with both the NPI and NPI-Q. Results: Positive and significant correlations were observed between the NPI-Q, 
the NPI, and the ACE-R (r=0.730; p<0.01 and 0.315; p<0.05 respectively). The instrument displayed an adequate 
level of reliability (Cronbach’s alpha=0.783). The most prevalent NPS were apathy/indifference (62.3%) and dysphoria/
depression (58.5%). Conclusion: The NPI-Q exhibited acceptable validity and reliability indicators for patients with AD 
in Chile, indicating that it is a suitable instrument for the routine assessment of NPS in clinical practice.
Key words: dementia, assessment, neuropsychiatric inventory, Alzheimer’s disease, prevalence, neuropsychiatric 
symptoms.
UTILIDADE DO QUESTIONÁRIO DE INVENTÁRIO NEUROPSIQUIÁTRICO (NPI-Q) NA AVALIAÇÃO DE UMA AMOSTRA DE 
PACIENTES COM DOENÇA DE ALZHEIMER NO CHILE
RESUMO. O Questionário de Inventário Neuropsiquiátrico (NPI-Q) é um instrumento baseado em informantes que mede a 
presença e a gravidade de 12 Sintomas Neuropsiquiátricos (NPS) em pacientes com demência, bem como o sofrimento 
do informante. Objetivo: Avaliar as propriedades psicométricas do NPI-Q e a prevalência de NPS em pacientes com 
doença de Alzheimer (DA). Métodos: Foram avaliados 53 pacientes com DA. Eles foram divididos em dois grupos 
diferentes: AD leve (n=26) e AD moderado (n=27). A validade convergente foi estimada correlacionando os resultados 
do NPI-Q com os escores do Inventário Neuropsiquiátrico (NPI) e um teste de eficiência cognitiva global (Addenbrooke’s 
Cognitive Examination – Revised – ACE-R). A confiabilidade do NPI-Q foi analisada pelo cálculo da sua consistência 
interna. A prevalência de NPS foi estimada com NPI e NPI-Q. Resultados: Foram observadas correlações positivas 
e significativas entre NPI-Q, NPI e ACE-R (r=0,730; p<0,01 e 0,315; p<0,05). O instrumento apresentou um nível 
adequado de confiabilidade (alfa de Cronbach=0,783). Os NPS mais prevalentes foram apatia/indiferença (62,3%) e 
disforia/depressão (58,5%). Conclusão: O NPI-Q apresenta indicadores de validade e confiabilidade aceitáveis  em 
pacientes com DA, o que indica que é um instrumento adequado para a avaliação rotineira de NPS na prática clínica.
Palavras-chave: demência, avaliação, inventário neuropsiquiátrico, doença de Alzheimer, prevalência, sintomas 
neuropsiquiátricos.
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INTRODUCTION
Life expectancy in Latin America has rapidly increased over recent years. Chile has one of the highest rates 
of population ageing within the zone, with 11.4% 
growth in individuals aged 60 or older.1,2 Dementia is 
the most frequent mental disorder in this population 
and cases worldwide are expected to increase 68% by 
2050. The estimated number of people with dementia 
in Chile was 150,293 in 2010, 181,761 in 2015 and is 
set to reach 533,188 in 2050.3 Additionally, the depen-
dency rate associated with dementia is estimated to be 
roughly 37.8% higher than that of the general popula-
tion. Concerning different types of dementia and their 
frequency, Alzheimer’s disease (AD) is the most preva-
lent subtype, accounting for approximately 70% of all 
cases. The second most common cause of dementia is 
vascular dementia, accounting for 10-20% of cases, fol-
lowed by Frontotemporal and Lewy Body dementias.4,5
Regardless of the type of dementia, besides its char-
acteristic progressive cognitive and functional impair-
ment, this syndrome is usually accompanied by behav-
ioral disorders, also referred to as Neuropsychiatric 
Symptoms (NPS), which can be defined as non-cogni-
tive/behavioral symptoms that include mood, percep-
tion, and behavior alterations.6 In terms of the likely 
emergence of NPS, several studies have indicated that 
more than 80% of patients with dementia experience 
at least one NPS,6 with increasing severity as the dis-
ease progresses.7,8 Similarly, data from the Cache County 
Study showed a 97% prevalence of at least one NPS with 
the most frequent symptoms being depression (77%), 
apathy (71%) and anxiety (62%).9
There are different types of NPS, probably due to the 
various etiological mechanisms that underpin each type 
of dementia.8-10 Exploring the likely presence of NPS in 
patients with dementia is critical for an appropriate dif-
ferential diagnosis. Their assessment is important given 
the relationship existing between the presence of NPS 
and decline in quality of life, increased institutionaliza-
tion, and rise in patient mortality.11 These issues result 
in a high level of caregiver burden and greater economic 
costs because of the frequent use of medication.9-12
Complementary, NPS assessment is relevant in 
dementia care, considering that it might provide an 
insight into the management of the behavioural dis-
orders emerging from the difficulties of each case, 
given that they become more frequent as the disease 
progresses.
In this context, appropriate assessment of NPS 
becomes extremely important for the differential 
diagnosis of dementia, its related clinical practice, and 
the assessment of patients’ behavioural response to 
treatments.
One of the most common scales for assessing the 
presence and severity of NPS in dementia is the Neu-
ropsychiatric Inventory (NPI),13 a carer-based tool that 
assesses the possible presence of 12 symptoms in demen-
tia cases, including delusions, hallucinations, agitation/ 
aggression, dysphoria/depression, anxiety, euphoria/ela-
tion, apathy/indifference, disinhibition, irritability/labil-
ity, aberrant motor behaviors, night-time behavioral dis-
turbances and appetite/eating disturbances. This scale 
is very useful and widely employed in research; how-
ever, its administration is time-consuming for health 
professionals, discouraging its inclusion in everyday 
clinical practice. In order to tackle this drawback, Kaufer 
et al.14 developed a shorter version of the instrument: 
the Neuropsychiatric Inventory Questionnaire (NPI-Q), 
another informant-based instrument that is easier to 
administer in both clinical and research settings. This 
questionnaire assesses the possible presence of the same 
12 NPS included in the NPI and also provides an index 
to grade the corresponding severity of each symptom 
and the respective distress it causes on the caregiver. 
The Spanish version of the NPI-Q developed by Boada 
et al. has shown appropriate validity and reliability in 
Spain.15 Nevertheless, in Latin America it has been vali-
dated only for Brazil16 and Mexico17 so far, while valida-
tion in other Latin American countries, including Chile, 
remains pending.
The main objective of this study was to assess the psy-
chometric properties of the NPI-Q in Chile. The second-
ary objective was to compare the prevalence and severity 
of NPS in a Chilean sample comprising patients with AD.
METHODS
Participants. A convenience sample of 53 patients with 
mild and moderate AD and their respective caregivers 
was included in this study. AD diagnoses were estab-
lished by a neurologist based both on the Clinical 
Dementia Rating Scale (CDR)18 and on the National 
Institute of Neurological and Communicative Disorders 
and Strokes and the Alzheimer’s Disease and Related 
Disorders Association – NINCDS-ADRDA – criteria.19 
The subdivision of the sample into two different 
groups was done according to CDR Global Score: mild 
AD (n=26; CDR=1) and moderate AD (n=27; CDR>2). 
The inclusion criteria considered participants of both 
sexes, over 65 years old, Spanish speakers, and with 
at least 4 years of education. Patients were recruited 
from the Cognitive Neurology and Dementia Unit 
of the Neurology Service at the Hospital del Salvador 
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and from the Neurology and Neurosurgery Service at 
the Hospital Clínico Universidad de Chile (HCUCH) 
in Santiago, Chile. Each participant was asked to 
sign an informed consent form, revised by the Ethics 
Committee of the West Metropolitan Health Service 
and that of the HCUCH in Santiago, Chile. All the 
subjects with AD underwent a full neurological exami-
nation, a neuropsychological assessment, and neuro-
imaging procedures (Structural Magnetic Resonance) 
to confirm their diagnoses. The exclusion criteria were 
severe sensory deficits (hearing and vision), a history of 
strokes, and major psychiatric disorders.
Instruments
Neuropsychiatric Inventory (NPI). The NPI13 is a retro-
spective (1 month) caregiver/informant-based inter-
view covering 12 NPS, including delusions, hallucina-
tions, agitation/aggression, dysphoria/depression, 
anxiety, euphoria/elation, apathy/indifference, disin-
hibition, irritability/lability, aberrant motor behav-
iors, night-time behavioral disturbances and appe-
tite/eating disturbances. The scripted NPI interview 
includes a compound screening question for each 
symptom domain, followed by a list of questions 
about domain specific behaviors administered when 
a positive response to a screening question is elicited. 
Neuropsychiatric symptoms are rated by the caregiver 
within a domain in terms of both frequency (1=rarely, 
less than once per week; 2=sometimes, about once per 
week; 3=often, several times per week; and 4=very 
often, once or more per day) and severity (1=mild; 
2=moderate; 3=severe), thus yielding a composite 
symptom domain score (frequency × severity) ranging 
from 0 (absence of behavioral symptoms) to 144 
points (maximum severity of behavioral symptoms). 
Frequency and severity rating scales have anchor points 
to enhance the reliability of caregiver responses. Care-
giver distress is rated for each positive neuropsychiatric 
symptom domain on a scale anchored by scores from 0 
to 5 points (0=no distress; 1=minimal distress; 2=mild 
distress; 3=moderate distress; 4=severe distress; and 
5=very severe distress). The NPI is administered as a 
structured interview taking roughly 20 minutes.
Neuropsychiatric Inventory Questionnaire (NPI-Q). The 
NPI-Q14 is a caregiver-based questionnaire in which the 
carer indicates the presence or absence of NPS in the 
patient during the last few weeks. It can be completed 
in 5 to 10 minutes and assesses the same 12 behavioral 
symptoms as the NPI; however, unlike the NPI, the 
NPI-Q only considers the severity of NPS and caregiver 
distress. The severity scale has scores ranging from 1 to 
3 points (1=mild; 2=moderate; and 3=severe) and the 
scale for assessing caregiver distress has scores ranging 
from 0 to 5 points (0=no distress; 1=minimal distress; 
2=mild distress; 3=moderate distress; 4=severe distress; 
and 5=extreme distress). The NPI-Q has proven valid 
and has acceptable levels of internal consistency.14 
Other instruments. In addition, the Addenbrooke’s Cogni-
tive Examination - Revised - Chilean Version - (ACE-R-
Ch)20 and the CDR18 were administered as a measure 
of global cognitive efficiency and dementia severity 
respectively.
Procedure and data analysis. Firstly, the NPI was admin-
istered to the primary caregiver of each patient with 
AD included in this study. Subsequently, the NPI-Q was 
filled in by the same carer two weeks later. This gap of 
two weeks between the administration of the NPI and 
the NPI-Q was due to logistical reasons. It was assumed 
that this interval had no influence on patients’ behav-
ioural changes, as all the participants in this study had 
stable clinical pictures during the preceding 6 months 
of assessment. 
The statistical analysis was performed with the IBM 
SPSS 22 package.21 Descriptive demographic data and 
clinical profiles were obtained for the sample. A com-
parative analysis was conducted to estimate the preva-
lence of NPS in this sample of AD patients according 
to the NPI and the NPI-Q. The Chi-squared test was 
employed to compare and assess whether there were 
significant differences between the scales in terms of 
the frequency/percentage of each symptom. The Mann-
Whitney U test for independent samples was used to 
compare the two groups (CDR=1 and 2) and detect sig-
nificant differences in the means of each NPS.
In order to estimate the convergent validity of 
the instrument, a correlation analysis was performed 
according to the distribution of each variable (Pearson’s 
r or Spearman’s rho where appropriate) among the 
NPI (total score, severity, distress, and by domain), the 
NPI-Q (total score, severity, distress, and by domain), 
and the ACE-R-Ch. In order to determine the reliabil-
ity of the NPI-Q, its internal consistency was estimated 
with Cronbach’s alpha.
RESULTS
Demographic data and clinical profiles. Table 1 summa-
rizes the demographic and clinical data of the total 
sample (n=53). The sample was divided, according to 
CDR scores, into CDR=1 (n=26) and CDR=2 (n=27). 
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Concerning clinical profiles, significant differences 
were found between the groups (p<0.05) in global 
cognitive efficiency measures (ACE-R-Ch), Total NPI, 
Total NPI-Q, and NPI-Q Distress.
NPI-Q. All the patients displayed at least one neuropsy-
chiatric symptom on both the NPI and NPI-Q scales 
(Table 1).
The correlation between the NPI total score (sum of 
the products of severity per frequency of all domains) 
and the NPI-Q total score (sum of the severity scale of 
all domains) was positive, high, and significant (r=0.73; 
p<0.01). Similarly, the correlation between the scores 
on the NPI and NPI-Q distress scales was positive, high, 
and significant (r=0.715; p<0.01).
Regarding the ACE-R, a negative, moderate and sig-
nificant correlation index was observed between the 
ACE-R-Ch and the total NPI-Q score (r=-0.315; p<0.01) 
(Table 2)
Correlating the presence of symptoms in terms 
of the NPI and NPI-Q, the per-domain correlations 
indicated a range of values between 0.292 and 0.708 
(p<0.01). According to the score on each domain, sig-
nificant correlations were found (p<0.05), ranging from 
0.383 to 0.962, for hallucinations, dysphoria/depres-
sion, anxiety, apathy/indifference, night-time and 
appetite/eating disturbances. The distress scale showed 
the smallest number of symptoms that correlated with 
each other. Despite this, dysphoria/depression, anxiety, 
apathy/indifference, and irritability were the only NPS 
that showed significant values, ranging from p=0.438 to 
p=0.627 (p<0.05) (Table 3). In addition, the instrument 
displayed a good level of internal consistency (Cron-
bach’s alpha=0.783).
The prevalence of the neuropsychiatric symptoms 
was analyzed using both scales. According to the NPI-
Q, the most frequent NPS in AD was apathy/indiffer-
ence (62.3%), followed by dysphoria/depression (58.5%) 
and irritability (52.8%). The least frequent NPS in AD 
were hallucinations (17%) and euphoria/elation (11.3%) 
(Figure 1).
A significant proportion of the NPS had non-signif-
icant differences between the NPI and the NPI-Q. Nev-
ertheless, euphoria/elation was the only NPS whose 
Table 1. Clinical and demographic data.
Variable All (n=53) CDR=1 (n=26) CDR=2 (n=27) Caregivers
Age 73.8±6.87 74.4±6.5 73.3±6.3 63.66±12.66
Education (years) 11.5±4.82 12.2±4.6 10.9±4.9 12.32±5.05
Total ACE-R score* 61.02±16.18 70.2±12.5 52.2±14.4
Total NPI score* 17.58±20.61 11.6±12.8 23.3±24.9
NPI – Distress score 8.21±8.63 5.9±7.2 10.4±9.4
Total NPI-Q score* 8.64±6.54 6.3±4.8 10.5±7.2
NPI-Q – Distress score* 11.09±9.87 7.4±7.9 14.1±10.4
Results expressed as Mean±Standard Deviation. *Groups differ significantly (p> 0.05)
Table 2. Inter-scale correlations among the NPI, NPI-Q, and ACE-R-Ch.
Variables All (n=53) CDR=1 (n=26) CDR=2 (n=27)
NPI-Q –Total/NPI - Totalb 0.730** 0.725** 0.691**
NPI-Q – Distress/NPI - Distressb 0.715** 0.671** 0.671**
NPI-Q – Total/NPI-Q - Distressb 0.900** 0.818** 0.912**
NPI – Total/NPI - Distressb 0.882** 0.834** 0.929**
NPI-Q – Total/ACE-Ra –0.315* n.s. n.s.
NPI – Total/ACE-Ra n.s. n.s. n.s.
*p< 0.05; **p< 0.01; n.s.: Non-significant. aPearson’s correlation coefficient (r). bSpearman’s correlation coefficient (r).
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Table 3. Inter-scale correlations between the NPI and the NPI-Q.
Domain NPI-Q Symptom/NPI NPI-Q - Total/NPI - Total NPI-Q - Distress/NPI - Distress
Delusionsa 0.628** 0.678 n.s.
Hallucinationsa 0.542** 0.962* n.s.
Agitation/Aggressiona 0.413** n.s. n.s.
Dysphoria/Depressionb 0.653** 0.383* 0.438**
Anxietyb 0.673** 0.499* 0.594**
Euphoria/Elationb 0.292* -- 1
Apathy/Indifferenceb 0.450** 0.433* 0.627**
Disinhibitionb 0.632** n.s. n.s.
Irritability/Labilityb 0.708** 0.419* 0.496**
Aberrant Motor Behaviorb 0.522** n.s. n.s.
Nighttime Behavioral Disturbancesb 0.676** 0.861** n.s.
Appetite/Eating Disturbancesb 0.580** 0.655* n.s.
*p< 0.05; **p< 0.01; n.s.: Non-significant. aPearson’s correlation coefficient (r). bSpearman’s correlation coefficient (r).
Delusions Hallucinations Agitation /Aggression
Dysphoria /
Depression Anxiety
Euphoria /
Elation Apathy Disinhibition Irritability
Aberrant
Motor
Behavior
Nighttime
disturbances
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disturbances
NPI 18.9 9.4 32.1 56.6 50.9 9.4 58.5 24.5 45.3 28.3 24.5 35.8
NPI-Q 30.2 17 26.4 58.5 41.5 11.3 62.3 22.6 52.8 34 30.2 24.5
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Figure 1. Comparison of the prevalence of neuropsychiatric symptoms in patients with AD using the NPI and the NPI-Q.
prevalence differed significantly between the two scales 
(Chi-squared=4.5; p> 0.05) (Figure 1).
The comparison of the sample according to the 
severity of dementia (CDR=1 and CDR=2) revealed 
an increase in the prevalence of all NPS as the disease 
progressed, except for night-time disturbances, whose 
prevalence decreased. The symptoms whose prevalence 
showed the highest increase included delusions (44.2%), 
agitation/aggression (36.7%), and aberrant motor 
behavior (28.9%) (Figure 2). Significant differences were 
observed between the two groups regarding the pres-
ence of delusions, agitation/aggression, and aberrant 
motor behavior (Figure 2).
DISCUSSION
The first aim of this study was to examine the psycho-
metric properties and utility of the NPI-Q in a Chilean 
sample of patients with AD, given that one of the main 
purposes of this instrument is to facilitate the routine 
assessment of NPS for dementia cases in everyday 
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Figure 2. Prevalence of neuropsychiatric symptoms according to the NPI-Q in patients with mild (CDR=1) and moderate (CDR=2) AD.
Delusions Hallucinations Agitation /Aggression
Dysphoria /
Depression Anxiety
Euphoria /
Elation Apathy Disinhibition Irritability
Aberrant
Motor
Behavior
Nighttime
disturbances
Appetite /
Eating
disturbances
CDR =1 7.7 7.7 7.7 46.2 30.8 7.7 50 11.5 50 19.2 30.8 23.1
CDR=2 51.9 25.9 44.4 70.4 51.9 14.8 74.1 33.3 55.6 48.1 29.6 25.9
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clinical practice settings. The second goal of the study 
was to analyze the frequency of NPS in AD in Chile and 
to identify any possible differences associated with the 
severity of dementia.
The following section provides a detailed analysis of 
these results.
Psychometric properties. The NPI-Q showed appropriate 
convergent validity and internal reliability with respect 
to total and individual symptom domain scores and 
caregiver distress ratings on the NPI. Both results are in 
accordance with those reported in the validation of the 
original scale14 and with those of the Spanish version.15
The NPI-Q distress scale was strongly and very sig-
nificantly associated with the severity of NPS. These 
results are consistent with those reported in previous 
studies analyzing the impact of NPS on caregiver bur-
den and quality of life. Kochhann et al.22 studied this 
association and concluded that NPS in patients with AD 
are the main cause of caregiver distress and burden, and 
that this association becomes stronger as the severity of 
dementia increases.
The NPI-Q symptom severity scale showed a strong 
correlation with both the severity scale and with the 
composite frequency × severity score (total score) from 
the NPI, with the correlation index remaining stable 
regardless of the severity of dementia (once the sample 
had been divided according to CDR). These results are 
also in line with the original studies.14,15
Thus, the present study provides sufficient evidence 
to assert that the NPI-Q had acceptable psychometric 
properties when tested in a cohort of Chilean patients 
with AD.
Neuropsychiatric symptom frequency. According to prior 
research, over 80% of patients with dementia expe-
rience at least one NPS.6,7 The results of the present 
study showed similar indexes, as 100% of the patients 
included in the sample displayed at least one neuropsy-
chiatric symptom according to the NPI and NPI-Q.
Based on the results obtained in this study, the 
most common NPS in patients with AD in Chile was 
apathy/indifference, followed by dysphoria/depression 
and irritability. In contrast, the least frequent symp-
toms were hallucinations and euphoria/elation. Only 
irritability was more prevalent in comparison with the 
results published by Qing-Fei et al.23 These researchers, 
from a meta-analysis of prior studies, concluded that 
the most frequent NPS in AD were apathy/indifference, 
dysphoria/depression, agitation/aggression, anxiety, 
night-time behavioural disturbances, and irritability, in 
decreasing order of prevalence.
Our results are consistent with findings of another 
study conducted in Chile that showed apathy/indiffer-
ence, anxiety, and irritability to be the most prevalent 
symptoms in these patients;24 in addition, the present 
study indicated that dysphoria/depression is one of the 
main NPS observed in AD.
Comparing the prevalence of NPS according to the 
severity of dementia, our results showed that only 
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night-time disturbances decreased, whereas delusions, 
agitation/aggression, and aberrant motor behavior 
increased as the disease progressed. In a longitudinal 
study, Brodaty et al.25 concluded that symptoms such as 
depression, euphoria/elation, and night-time and eat-
ing disturbances did not increase significantly in fre-
quency, but hallucinations, agitation/aggression, aber-
rant motor behavior, and apathy/indifference, among 
other symptoms, became more prevalent. By contrast, 
Bergh and Selbæk,26 also in a meta-analysis, concluded 
that although the course of NPS is heterogeneous, most 
display some increase, where aggression was the most 
persistent symptom.26
The prevalence of NPS assessed by the two scales dif-
fered by 6.1% overall in this study, and depending on 
the specific domain, tended to be higher or lower on the 
NPI-Q. This result is consistent with the original vali-
dation of the NPI-Q14 and its Spanish version,15 which 
showed differences of 5% and 6.7%, respectively. These 
differences in prevalence between the two scales could 
be explained by the fluctuations in NPS over time. 
The NPI-Q is also useful because it provides an indi-
cator for assessing global and NPS-related caregiver dis-
tress; in fact, it has already been used in multiple studies 
assessing this variable,27-29 allowing planning of person-
alized intervention strategies for caregivers.
Limitations. This study was conducted in caregivers/
informants with an average educational level where 
the administration of the questionnaires was aided by 
professionals when questions were not readily under-
stood. This point is of special consideration for clinical 
practice, particularly when involving low socioeco-
nomic status population groups whose understanding 
of the questions may be limited. Likewise, it is advis-
able for the administration of the NPI-Q to be assisted 
or alternatively, the instrument can be used as a brief 
interview, which should facilitate and ensure faithful 
representation of the patient’s reality.
One of the main limitations of our study is the 
inclusion of only AD patients. Further studies should 
include other dementia and neuropsychiatric condi-
tions to determine the validity of NPI in other diseases. 
Nevertheless, previous evidence in other countries sup-
ports the extrapolation of the NPI-Q to other forms of 
dementia.
In summary, given the good psychometric properties 
and utility of the NPI-Q scale, it can be concluded that 
the instrument is suitable for assessing NPS in demen-
tias in everyday clinical practice in Chile, having proven 
being brief, simple, valid, and reliable. 
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